Related Experiment Video
Updated: Dec 30, 2025

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
Published on: May 16, 2012
NUAK1 knockdown suppresses prostate cancer cell epithelial-mesenchymal transition, migration, and invasion through
Yongjun Guan1, Hongbo Shi1, Tianlin Xiao1
1Department of Urology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science China.
Objective:
Prostate cancer is one of the most diagnosed malignancies in men worldwide. Novel (nua) kinase family 1 (NUAK1) is a member of adenosine monophosphate (AMP)-related kinase which participates in varying cancers progression. However, the role of NUAK1 in prostate tumorigenesis has not been fully characterized. The aim of this study was to elucidate the potential biological role of NUAK1 in prostate cancer.
Methods:
Quantitative real-time PCR (qRT-PCR) was performed to determine the expression levels of NUAK1 and microRNA-30b-5p (miRNA-30b-5p) in prostate cancer cell lines and samples. Western blot was conducted to explore the related protein levels of epithelial-mesenchymal transition (EMT) and NUAK1 expression in prostate cancer cells. Trans-well test was used to assay prostate cancer cell migration and invasion. Luciferase assays were employed to probe the interaction between NUAK1 and miR-30b-5p.
Results:
NUAK1 abundance was enhanced in prostate cancer tissues and cell lines. The knockdown of NUAK1 may inhibit prostate cancer cells EMT, migration and invasion. Luciferase assays suggested NUAK1 was a target gene of miR-30b-5p. Furthermore, miR-30b-5p suppressed EMT, migration, and invasion in prostate cancer cells and introduction of NUAK1 abated the inhibitory effect.
Conclusions:
Both of NUAK1 and miR-30b-5p were required for prostate cancer progression. NUAK1 interference limited prostate cancer cell EMT, migration and invasion by miRNA-30b-5p modulating, providing a promising therapeutic approach for prostate cancer.
Insights
Novel kinase family 1 (NUAK1) and microRNA-30b-5p (miRNA-30b-5p) are crucial for prostate cancer progression. Inhibiting NUAK1 can limit cancer cell invasion and migration, offering a potential therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Prostate cancer is a leading malignancy in men globally.
- The role of Novel (NU) kinase family 1 (NUAK1) in prostate cancer development is not fully understood.
- NUAK1 is an AMP-activated protein kinase family member implicated in various cancers.
Purpose of the Study:
- To investigate the biological role of NUAK1 in prostate cancer.
- To elucidate the relationship between NUAK1 and microRNA-30b-5p (miRNA-30b-5p) in prostate cancer.
- To assess the potential of targeting NUAK1 for prostate cancer therapy.
Main Methods:
- Quantitative real-time PCR (qRT-PCR) to measure NUAK1 and miRNA-30b-5p expression.
- Western blot analysis for epithelial-mesenchymal transition (EMT) markers and NUAK1 protein.
- Trans-well assays for cell migration and invasion.
- Luciferase reporter assays to confirm NUAK1-miRNA-30b-5p interaction.
Main Results:
- NUAK1 expression was significantly elevated in prostate cancer tissues and cell lines.
- NUAK1 knockdown suppressed prostate cancer cell EMT, migration, and invasion.
- NUAK1 was identified as a direct target of miRNA-30b-5p.
- miRNA-30b-5p inhibited prostate cancer cell EMT, migration, and invasion, an effect reversed by NUAK1 overexpression.
Conclusions:
- Both NUAK1 and miRNA-30b-5p play essential roles in prostate cancer progression.
- NUAK1 interference, mediated by miRNA-30b-5p, effectively limits prostate cancer cell EMT, migration, and invasion.
- Targeting the NUAK1/miRNA-30b-5p axis presents a promising therapeutic avenue for prostate cancer.
Related Concept Videos
MicroRNAs
MicroRNAs
Abnormal Proliferation

